1. Home
  2. CMCL vs CMPX Comparison

CMCL vs CMPX Comparison

Compare CMCL & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Caledonia Mining Corporation Plc

CMCL

Caledonia Mining Corporation Plc

HOLD

Current Price

$21.65

Market Cap

373.1M

ML Signal

HOLD

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$2.16

Market Cap

408.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMCL
CMPX
Founded
1992
2014
Country
Jersey
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
373.1M
408.8M
IPO Year
2003
2020

Fundamental Metrics

Financial Performance
Metric
CMCL
CMPX
Price
$21.65
$2.16
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
9
Target Price
$28.00
$14.57
AVG Volume (30 Days)
218.2K
2.6M
Earning Date
05-11-2026
05-06-2026
Dividend Yield
2.48%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$38.54
N/A
Revenue Next Year
N/A
$934.41
P/E Ratio
$10.88
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.85
$1.61
52 Week High
$38.75
$6.88

Technical Indicators

Market Signals
Indicator
CMCL
CMPX
Relative Strength Index (RSI) 59.55 45.27
Support Level $18.45 $1.88
Resistance Level $20.45 $2.02
Average True Range (ATR) 0.73 0.11
MACD 0.36 -0.01
Stochastic Oscillator 88.52 37.33

Price Performance

Historical Comparison
CMCL
CMPX

About CMCL Caledonia Mining Corporation Plc

Caledonia Mining Corp PLC is a gold exploration, development, and mining company. The company's segment includes Blanket, South Africa, Bilboes Oxide mine, and E&E projects. The company generates the majority of its revenue from the Blanket project. The Blanket Mine is located in the south-west of Zimbabwe and operates at a depth of approximately 750 meters below the surface. Its project includes Maligreen and Motapa.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

Share on Social Networks: